|Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.||Chairman of Management Board & CEO||1.06M||N/A||1968|
|Mr. Enno Spillner||CFO & Member of Management Board||608k||N/A||1970|
|Dr. Cord Dohrmann Ph.D.||Chief Scientific Officer & Member of Management Board||792k||N/A||1964|
|Dr. Craig Johnstone||COO & Member of Management Board||618k||N/A||1970|
|Ms. Anja Bosler||Principal Accounting Officer and Sr. VP of Group Accounting||N/A||N/A||N/A|
|Mr. Volker Braun||Sr. VP and Global Head of Investor Relations & ESG||N/A||N/A||N/A|
|Dr. Christian Dargel||EVP Global Head of Legal & Compliance||N/A||N/A||N/A|
|Gabriele Hansen||Sr. VP of Corp. Communications, Marketing & Investor Relations||N/A||N/A||N/A|
|Ms. Monika Conradt||Global Head of HR||N/A||N/A||N/A|
|Dr. Ian M. Hunneyball||Sr. VP of Programme Management & Clinical Operations||N/A||N/A||1950|
Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health. It has collaboration agreements with Bayer AG; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Celgene; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Evotec SE’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 1; Compensation: 7.